// App-Quantinova.ai

: Unique immune signatures predict potential cardiometabolic risk in severe COVID-19 patients and COVID-19 recovered individuals

Researchers

Presenter

  • Namal Liyanage

Principal Investigators

  • Manuja Gunasena

  • Yasasvi Wijewantha

  • Emily Bowman

  • Janelle Gabriel

  • Amrendra Kumar

  • Aaren Kettelhut

  • Anushka Ruwanpathirana

  • Krishanthi Weragalaarachchi

  • Dhanuja Kasturiratna

  • Anna Vilgelm

  • Sonal Pannu

  • Joseph Bednash

  • Thorsten Demberg

  • Nicholas Funderburg

Medical Centers

  • Department of Microbial Infection and Immunity, The Ohio State University

  • Department of Microbial Infection and Immunity, The Ohio State University

  • Eastern Kentucky University

  • Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University

  • Marker Therapeutics Inc., Houston, TX, United States

  • The Ohio State University, College of Medicine

  • College of Medicine, The Ohio State University, Columbus, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Infectious Diseases (ID)

Disease

  • Venous thrombosis

  • Coronavirus disease

Biomarkers

  • TIMP Metallopeptidase Inhibitor 1

  • TIMP Metallopeptidase Inhibitor 2

Drug/Treatment

  • TIMP-2

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved